Detection of early stage heart failure – 1st Phase Ejection Fraction (EF1) [Assigned to Inventors - keep open as Revenue Share applies]

An accurate test for detecting patients with abnormal left ventricle function in early heart failure when ejection fraction is preserved. This could prove an invaluable tool for the early diagnosis and improved prognosis of patients with heart failure.




Heart failure (HF) is a syndrome that occurs as a result of abnormal function of the left ventricle. Prevalence increases with age and prognosis is poor, often as a consequence of late diagnosis. Improved pharmacological and non-pharmacological interventions are currently in development which, with improved diagnosis, may be more effectively deployed.

Ejection fraction (EF), a measure of the percentage of blood volume ejected from the left ventricle during systole, has been used as the “gold standard” for assessing left ventricle function and thus for diagnosing HF. EF can readily be measured by ultrasound or cardiac magnetic imaging modalities.

However, it is now recognised that EF is preserved in many patients with HF thus rendering the above measurement ineffective. Improved methods of detecting abnormal left ventricle function are therefore urgently required to more effectively diagnose patients with HF when EF is preserved.


Test Procedure


The present invention relates to a simple, but effective test for detecting patients with abnormal left ventricle function in early stage HF when EF is preserved. This is achieved by measuring the early ejection fraction (EF1). EF1 measures the percentage of left ventricle volume change from the beginning of systole to the time of the first pressure peak in the left ventricle waveform.


Commercial Opportunity


KCL is seeking a partner for the further development and validation of this opportunity. Both the patent application and clinical data are available for licensing.

Key Benefits


•       More sensitive than existing techniques

•       Easily implemented into existing software

•       Non-invasive




EF1 has been examined in patients with pre-clinical heart failure due to hypertension or valvular disease. It has been found to be more sensitive in detecting left ventricle dysfunction than state-of-art methods such as Global Longitudinal Strain (GLS) or Tissue Doppler imaging S wave.


Patent Information:
For Information, Contact:
Jenny Worthington
King's College London
Philip Chowienczyk
Haotian Gu